View Future GrowthDKSH Holding 過去の業績過去 基準チェック /36DKSH Holdingの収益は年間平均-1.1%の割合で減少していますが、 Trade Distributors業界の収益は年間 減少しています。収益は年間1.1% 0.1%割合で 減少しています。 DKSH Holdingの自己資本利益率は12.4%であり、純利益率は1.9%です。主要情報-1.08%収益成長率-0.80%EPS成長率Trade Distributors 業界の成長18.43%収益成長率-0.14%株主資本利益率12.40%ネット・マージン1.92%次回の業績アップデート16 Feb 2027最近の業績更新Reported Earnings • Jul 19First half 2026 earnings released: EPS: CHF1.67 (vs CHF1.41 in 1H 2025)First half 2026 results: EPS: CHF1.67 (up from CHF1.41 in 1H 2025). Revenue: CHF5.48b (flat on 1H 2025). Net income: CHF101.1m (up 10% from 1H 2025). Profit margin: 1.8% (in line with 1H 2025). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has fallen by 1% per year.お知らせ • Jun 19+ 1 more updateDKSH Holding AG to Report First Half, 2027 Results on Jul 19, 2027DKSH Holding AG announced that they will report first half, 2027 results on Jul 19, 2027Reported Earnings • Feb 19Full year 2025 earnings released: EPS: CHF3.12 (vs CHF3.31 in FY 2024)Full year 2025 results: EPS: CHF3.12 (down from CHF3.31 in FY 2024). Revenue: CHF11.1b (flat on FY 2024). Net income: CHF202.9m (down 5.5% from FY 2024). Profit margin: 1.8% (down from 1.9% in FY 2024). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 20First half 2025 earnings: EPS misses analyst expectationsFirst half 2025 results: EPS: CHF1.41 (down from CHF1.71 in 1H 2024). Revenue: CHF5.53b (up 1.5% from 1H 2024). Net income: CHF91.8m (down 17% from 1H 2024). Profit margin: 1.7% (down from 2.0% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 9% per year.お知らせ • Jun 20+ 1 more updateDKSH Holding AG to Report Fiscal Year 2025 Results on Feb 17, 2026DKSH Holding AG announced that they will report fiscal year 2025 results on Feb 17, 2026お知らせ • Mar 07DKSH Holding AG to Report First Half, 2025 Results on Jul 17, 2025DKSH Holding AG announced that they will report first half, 2025 results on Jul 17, 2025すべての更新を表示Recent updates分析記事 • Jul 22Analysts Are Updating Their DKSH Holding AG (VTX:DKSH) Estimates After Its Interim ResultsLast week, you might have seen that DKSH Holding AG ( VTX:DKSH ) released its half-yearly result to the market. The...Reported Earnings • Jul 19First half 2026 earnings released: EPS: CHF1.67 (vs CHF1.41 in 1H 2025)First half 2026 results: EPS: CHF1.67 (up from CHF1.41 in 1H 2025). Revenue: CHF5.48b (flat on 1H 2025). Net income: CHF101.1m (up 10% from 1H 2025). Profit margin: 1.8% (in line with 1H 2025). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has fallen by 1% per year.ナラティブ更新 • Jul 17DKSH: Expanded Asia Healthcare Partnerships Will Support Undervalued Distribution PlatformAnalysts have raised their price target on DKSH Holding to CHF 74.75 from CHF 72.57. They cite the company’s differentiated Asia exposure, as well as margin expansion and valuation re-rating potential highlighted in recent research.ライブニュース • Jul 07DKSH Expands Lilly Partnership to Cover Hong Kong and Macau Healthcare MarketsDKSH Holding has entered a partnership with Eli Lilly Export S.A. to sell, promote and distribute Lilly’s pharmaceutical products in Hong Kong SAR and Macau SAR, extending an existing collaboration that already covers Singapore and Vietnam. The arrangement uses DKSH’s healthcare infrastructure and commercial platform in the region, while Lilly’s patient support programs in Hong Kong and Macau are expected to remain fully operational under the new setup. DKSH’s share price is at CHF64.20, with the stock up 9.6% year to date. By deepening its relationship with a global pharmaceutical group like Eli Lilly, DKSH is adding scale and relevance to its healthcare segment in two dense, higher-income markets, which concentrates execution risk around product availability, regulatory compliance and service quality in those territories.お知らせ • Jun 19+ 1 more updateDKSH Holding AG to Report First Half, 2027 Results on Jul 19, 2027DKSH Holding AG announced that they will report first half, 2027 results on Jul 19, 2027お知らせ • Mar 30+ 1 more updateDKSH Holding AG Approves Board ElectionsDKSH Holding AG announced at annual general meeting held on March 27, 2026, the shareholders elected Corine Tap, and Julie von Wedel-Keller as new members of the Board of Directors.Upcoming Dividend • Mar 24Upcoming dividend of CHF2.50 per shareEligible shareholders must have bought the stock before 31 March 2026. Payment date: 02 April 2026. Payout ratio is on the higher end at 80%, however this is supported by cash flows. Trailing yield: 4.3%. Within top quartile of Swiss dividend payers (3.6%). Higher than average of industry peers (2.6%).お知らせ • Mar 23DKSH Holding AG(SWX:DKSH) dropped from FTSE All-World Index (USD)DKSH Holding AG(SWX:DKSH) dropped from FTSE All-World Index (USD)お知らせ • Mar 06DKSH Holding AG, Annual General Meeting, Mar 27, 2026DKSH Holding AG, Annual General Meeting, Mar 27, 2026, at 10:00 W. Europe Standard Time.Reported Earnings • Feb 19Full year 2025 earnings released: EPS: CHF3.12 (vs CHF3.31 in FY 2024)Full year 2025 results: EPS: CHF3.12 (down from CHF3.31 in FY 2024). Revenue: CHF11.1b (flat on FY 2024). Net income: CHF202.9m (down 5.5% from FY 2024). Profit margin: 1.8% (down from 1.9% in FY 2024). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • Feb 18DKSH Holding AG announces Annual dividend, payable on April 02, 2026DKSH Holding AG announced Annual dividend of CHF 2.5000 per share payable on April 02, 2026, ex-date on March 31, 2026 and record date on April 01, 2026.ナラティブ更新 • Feb 11DKSH: Potential Swixx Acquisition Will Support Undervalued Healthcare Distribution PlatformAnalysts have maintained their price target for DKSH Holding at around CHF 72.57. This suggests only very small adjustments in assumptions for the discount rate, long-term revenue growth, profit margin and future P/E to reflect updated risk and earnings expectations.ナラティブ更新 • Jan 27DKSH: Future Healthcare And Consumer Distribution Deals Will Support Undervalued SharesAnalysts have nudged their price target for DKSH Holding slightly higher, with fair value rising from CHF 72.17 to about CHF 72.57. This reflects small adjustments to assumptions around the discount rate, modestly stronger revenue growth, a marginally softer profit margin and a slightly higher future P/E multiple.お知らせ • Jan 16DKSH Management AG Announces Retirement of Thomas Sul from the Role as Co-Head and Member of the Executive CommitteeDKSH Management AG announced that Thomas Sul, Co-Head of the Business Unit Performance Materials and Member of the Executive Committee, has decided to gradually scale down his activities as he eases into retirement and has stepped down from his role as Co-Head and Member of the Executive Committee. Natale Capri, who has served as Co-Head for over ten years, assumes full responsibility as Head of the Business Unit Performance Materials and will remain a Member of the Executive Committee. After nearly 30 years at DKSH, Thomas Sul leaves behind a remarkable legacy. Under his co-leadership, Performance Materials has achieved significant milestones, including driving globalization, strengthening business development, realizing multiple acquisitions, and doubling operating profit. Thomas will continue to contribute his expertise in a strategic capacity after scaling down his activities in the first quarter of 2026.ナラティブ更新 • Jan 12DKSH: Future Asia Distribution Deals Will Support Undervalued Share PriceAnalysts have trimmed their price target on DKSH Holding to about CHF 72, down from roughly CHF 74, citing updated assumptions for fair value, discount rate, revenue growth, profit margins and a slightly higher future P/E multiple. What's in the News DKSH is reported to be among potential bidders for Swiss pharmaceutical distributor Swixx Biopharma, with the target company said to be valued in a range of €1.5b to €2b.お知らせ • Dec 19DKSH Holding AG (SWX:DKSH) agreed to acquire Biomedic Science Material Joint Stock Company.DKSH Holding AG (SWX:DKSH) agreed to acquire Biomedic Science Material Joint Stock Company on December 17, 2025. For the period ending December 31, 2024, Biomedic Science Material Joint Stock Company reported total revenue of CHF 12 million. The expected completion of the transaction is January 1, 2026 to March 31, 2026.分析記事 • Dec 15DKSH Holding (VTX:DKSH) Has More To Do To Multiply In Value Going ForwardIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...お知らせ • Nov 22DKSH Management Ltd. Announces Executive ChangesDKSH Management Ltd. announced the appointment of Patrik Grande as new Head Business Unit Healthcare as of January 2026. Currently Vice President, Commercial Outsourcing & Cluster Head APAC, he will be a member of DKSH's Executive Committee, report to CEO Stefan P. Butz, and will relocate from Bangkok to Singapore within the next year. Patrik Grande follows Bijay Singh who will begin his retirement on March 31, 2026, after eleven years at DKSH. Patrik Grande is a well-seasoned and accomplished leader with more than 20 years of experience in the global pharmaceutical industry. He joined DKSH in 2022 as Vice President, Business Unit Healthcare Thailand, following a successful two-decade career at Novartis. During his time at Novartis, he held increasingly senior leadership roles across multiple markets, including South Korea, Malaysia, the United Kingdom, Switzerland, Russia, and Spain. Since joining DKSH, Patrik has revitalized the Healthcare business in Thailand and delivered growth. In his role as Vice President, Commercial Outsourcing & Cluster Head APAC, he strengthened the strategic commercial outsourcing pillar, expanded the robust regional capabilities, delivering growth and driving strategic progress across the region. A Spanish citizen, Patrik holds a Master's degree in Business Administration from IESE Business School. Bijay Singh leaves behind an outstanding legacy after eleven years at DKSH, including nearly nine years as Head Business Unit Healthcare and Member of the Executive Committee. Bijay Singh joined DKSH as Vice President, Global Business Development for Business Unit Healthcare in 2015. His tenure was marked by significant achievements such as building robust commercial outsourcing capabilities, driving strategic M&As, expanding the Healthcare business into new markets such as Australia, the Philippines, and South Korea, and fostering a strong talent pipeline.お知らせ • Nov 18DKSH Reportedly to Weigh Bid for Pharma Distributor Swixx BiopharmaDKSH Holding AG (SWX:DKSH) is among the companies exploring a potential acquisition of Swiss pharmaceutical distributor Swixx Biopharma (Swixx Biopharma SA), Bloomberg News reported on November 16, 2025, citing people familiar with the matter. Private-equity firms SK Capital Partners (SK Capital Partners, LP) and Lone Star (Lone Star Americas Acquisitions, Inc.) are also said to be evaluating bids. The sources indicated that Swixx could fetch EUR 1.5 billion to EUR 2 billion ($1.7 billion to $2.2 billion), though talks are ongoing and may not lead to a deal. Additional bidders could still join the process. Swixx, jointly owned by HBM Healthcare Investments and members of its management team, specializes in helping drugmakers navigate distribution in smaller and more regulated markets. The company operates in 44 countries and recorded EUR 900 million in 2023 revenue, according to its website. Zurich-based DKSH, valued at roughly CHF 3.5 billion, runs a similar distribution and marketing platform spanning healthcare, consumer goods, technology and industrial materials. Representatives for DKSH, Lone Star and HBM declined to comment to Bloomberg News. SK Capital did not respond to a request for comment, and Swixx could not be reached.分析記事 • Nov 16The Price Is Right For DKSH Holding AG (VTX:DKSH)With a median price-to-earnings (or "P/E") ratio of close to 20x in Switzerland, you could be forgiven for feeling...ナラティブ更新 • Sep 06Asia Pacific Expansion And Digitalization Will Fuel Sustainable SuccessThe consensus analyst price target for DKSH Holding has been revised downward, reflecting modest declines in both revenue growth forecasts and the future P/E ratio, resulting in a new fair value of CHF74.00. What's in the News DKSH Consumer Goods has partnered with Nextfood Global to launch premium breakfast cereals and freeze-dried fruit snacks in Singapore, targeting health-conscious, urban consumers.分析記事 • Aug 26DKSH Holding (VTX:DKSH) Hasn't Managed To Accelerate Its ReturnsDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...分析記事 • Aug 08DKSH Holding (VTX:DKSH) Seems To Use Debt Quite SensiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Jul 20First half 2025 earnings: EPS misses analyst expectationsFirst half 2025 results: EPS: CHF1.41 (down from CHF1.71 in 1H 2024). Revenue: CHF5.53b (up 1.5% from 1H 2024). Net income: CHF91.8m (down 17% from 1H 2024). Profit margin: 1.7% (down from 2.0% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 9% per year.お知らせ • Jun 20+ 1 more updateDKSH Holding AG to Report Fiscal Year 2025 Results on Feb 17, 2026DKSH Holding AG announced that they will report fiscal year 2025 results on Feb 17, 2026お知らせ • May 21DKSH Holding AG (SWX:DKSH) signed an agreement to acquire A.P.N Plastics Pty Ltd.DKSH Holding AG (SWX:DKSH) signed an agreement to acquire A.P.N Plastics Pty Ltd on May 20, 2025. DKSH will acquire the entire business and fully integrate the company into its existing operations. APN Plastics generates annual net sales of more than CHF 25 million. The transaction is subject to customary closing conditions. The closing of the transaction is expected during the second quarter of 2025.Valuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CHF58.70, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 15x in the Trade Distributors industry in Europe. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CHF94.58 per share.お知らせ • Mar 29DKSH Holding AG Announces Board ChangesDKSH Holding AG at its Annual General Meeting held on 27 March 2025, announced Dr. Hans Christoph Tanner did not stand for reelection. Suwannee Ratthayabandith was elected as a new member of the Board of Directors.Upcoming Dividend • Mar 24Upcoming dividend of CHF2.35 per shareEligible shareholders must have bought the stock before 31 March 2025. Payment date: 02 April 2025. Payout ratio is a comfortable 71% and this is well supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of Swiss dividend payers (4.0%). Higher than average of industry peers (2.4%).お知らせ • Mar 07DKSH Holding AG to Report First Half, 2025 Results on Jul 17, 2025DKSH Holding AG announced that they will report first half, 2025 results on Jul 17, 2025お知らせ • Feb 28DKSH Holding AG, Annual General Meeting, Mar 27, 2025DKSH Holding AG, Annual General Meeting, Mar 27, 2025, at 10:00 W. Europe Standard Time.新しいナラティブ • Feb 23New Partnerships With Alcon And Ichitan Will Expand Market Presence And Efficiency Strategic priorities and M&A partnerships are set to enhance market position and drive significant revenue and earnings growth. Reported Earnings • Feb 13Full year 2024 earnings released: EPS: CHF3.31 (vs CHF2.80 in FY 2023)Full year 2024 results: EPS: CHF3.31 (up from CHF2.80 in FY 2023). Revenue: CHF11.1b (flat on FY 2023). Net income: CHF214.8m (up 18% from FY 2023). Profit margin: 1.9% (up from 1.6% in FY 2023). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 1% per year.お知らせ • Jan 07DKSH Holding AG (SWX:DKSH) acquired Clmo Technology Sdn. Bhd.DKSH Holding AG (SWX:DKSH) acquired Clmo Technology Sdn. Bhd. on January 7, 2025. Clmo Technology Sdn. Bhd.'s management team will join DKSH Holding AG’s business unit technology. DKSH Holding AG (SWX:DKSH) completed the acquisition of Clmo Technology Sdn. Bhd. on January 7, 2025.お知らせ • Dec 06DKSH Holding AG to Report Fiscal Year 2024 Results on Feb 12, 2025DKSH Holding AG announced that they will report fiscal year 2024 results on Feb 12, 2025お知らせ • Nov 13DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare DistributionDKSH Healthcare Business Unit, in partnership with Euris, is introducing ConnectPlus, a data-driven Customer Relationship Management (CRM) and Multi-Channel Engagement (MCE) platform aimed at transforming healthcare distribution across the Asia Pacific region. Designed to enhance productivity and operational efficiency, this platform provides a 360° view of healthcare professionals, streamlines MCE, and strengthens DKSH Healthcare's ability to tailor interactions and marketing strategies. The roll-out will start in Thailand in January 2025. With this new platform DKSH Healthcare reinforces its dedication to commercial excellence by enlarging possibilities and improving interactions with clients, customers, and patients. The introduction of ConnectPlus underscores DKSH Healthcare's commitment to harnessing digital solutions that orchestrate and maximize impact of both client and patient interactions, while upholding a high standard of operational excellence. ConnectPlus empowers DKSH to tap into the vast potential provided by the global healthcare big data market by delivering precise, targeted engagement strategies that cater to the unique needs of healthcare professionals, clients, and patients across the region. Furthermore, ConnectPlus is strategically designed to leverage the existing preference of face-to-face sales visits, by orchestrating personalized digital touchpoints, based on data driven insights, to prepare and enhance in-person interactions. The platform's ability to blend in-person and digital strategies is essential for maximizing outreach and driving meaningful engagement. By integrating advanced AI and analytics, ConnectPlus not only streamlines communication and marketing efforts but also personalizes interactions based on real-time data, ensuring relevance and impact. This marks a crucial milestone in DKSH Healthcare's journey towards fully integrating digital innovation into its operations, reinforcing its leadership in driving agility and efficiency within the rapidly evolving healthcare landscape.Reported Earnings • Jul 18First half 2024 earnings released: EPS: CHF1.71 (vs CHF1.59 in 1H 2023)First half 2024 results: EPS: CHF1.71 (up from CHF1.59 in 1H 2023). Revenue: CHF5.45b (down 3.3% from 1H 2023). Net income: CHF111.2m (up 7.5% from 1H 2023). Profit margin: 2.0% (up from 1.8% in 1H 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 4% per year.Upcoming Dividend • Mar 21Upcoming dividend of CHF2.25 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 03 April 2024. Payout ratio is on the higher end at 80%, however this is supported by cash flows. Trailing yield: 3.6%. Lower than top quartile of Swiss dividend payers (4.1%). Higher than average of industry peers (2.2%).Declared Dividend • Feb 29Dividend increased to CHF2.25Dividend of CHF2.25 is 4.7% higher than last year. Ex-date: 28th March 2024 Payment date: 3rd April 2024 Dividend yield will be 3.5%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is covered by both earnings (80% earnings payout ratio) and cash flows (43% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 30% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Feb 18Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: EPS: CHF2.80 (down from CHF3.10 in FY 2022). Revenue: CHF11.1b (down 2.2% from FY 2022). Net income: CHF182.0m (down 9.5% from FY 2022). Profit margin: 1.6% (down from 1.8% in FY 2022). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.3%. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 2% per year.お知らせ • Dec 23+ 2 more updatesDKSH Holding AG to Report First Half, 2024 Results on Jul 16, 2024DKSH Holding AG announced that they will report first half, 2024 results on Jul 16, 2024Price Target Changed • Nov 21Price target decreased by 7.4% to CHF73.90Down from CHF79.80, the current price target is an average from 6 analysts. New target price is 31% above last closing price of CHF56.50. Stock is down 22% over the past year. The company is forecast to post earnings per share of CHF3.16 for next year compared to CHF3.09 last year.お知らせ • Sep 19DKSH Holding AG (SWX:DKSH) agreed to acquire CS Company Ltd.DKSH Holding AG (SWX:DKSH) agreed to acquire CS Company Ltd on September 18, 2023. CS Company generates net sales of over CHF 35 million. The deal is expected to close in the fourth quarter, subject to certain conditions.Reported Earnings • Jul 20First half 2023 earnings released: EPS: CHF1.59 (vs CHF1.58 in 1H 2022)First half 2023 results: EPS: CHF1.59 (up from CHF1.58 in 1H 2022). Revenue: CHF5.63b (flat on 1H 2022). Net income: CHF103.4m (flat on 1H 2022). Profit margin: 1.8% (in line with 1H 2022). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Buying Opportunity • Jun 22Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 8.1%. The fair value is estimated to be CHF83.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 3.6% per annum. Earnings is also forecast to grow by 8.7% per annum over the same time period.お知らせ • May 31DKSH Holding AG to Report First Half, 2023 Results on Jul 18, 2023DKSH Holding AG announced that they will report first half, 2023 results on Jul 18, 2023Buying Opportunity • May 17Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 15%. The fair value is estimated to be CHF84.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 3.6% per annum. Earnings is also forecast to grow by 8.7% per annum over the same time period.Price Target Changed • May 12Price target decreased by 12% to CHF70.83Down from CHF80.83, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of CHF69.85. Stock is down 14% over the past year. The company is forecast to post earnings per share of CHF3.34 for next year compared to CHF3.09 last year.お知らせ • May 11DKSH Appoints Chris Ritchie as New Head Business Unit Consumer GoodsDKSH announced the appointment of Chris Ritchie as new Head Business Unit Consumer Goods as of mid-August 2023. Based in Singapore, he will be a member of DKSH's Executive Committee and report to CEO Stefan P. Butz. Chris Ritchie follows Terry Seremetis, who, after four years, decided to pursue his career opportunities outside of DKSH as announced on January 3, 2023. Chris Ritchie has 28 years of experience in the consumer goods industry. For the last four years, he was Chief Global Business Officer of Sazerac, a leading privately held American spirit company, where he oversaw operations in Asia Pacific and Europe. From 2016 to 2019, he was General Manager at Reckitt Benckiser, responsible for the growth market Philippines. Prior to that, from 2007 to 2016, he held various General Manager and Director positions at SABMiller in Asia, Europe, and Americas, including Managing Director of SABMiller Vietnam. From 1995 to 2006, he held regional and global marketing roles at P&G. Throughout his career, Chris has driven growth, route-to-market, and built strong teams, especially in developing markets. A Canadian citizen,Chris (50 years) holds a Bachelor's degree in Economics from Queen's University in Kingston, Canada.Buying Opportunity • Mar 18Now 21% undervaluedOver the last 90 days, the stock is up 3.3%. The fair value is estimated to be CHF92.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 3.9% per annum. Earnings is also forecast to grow by 8.9% per annum over the same time period.Upcoming Dividend • Mar 13Upcoming dividend of CHF2.15 per share at 2.8% yieldEligible shareholders must have bought the stock before 20 March 2023. Payment date: 22 March 2023. Payout ratio is a comfortable 69% and this is well supported by cash flows. Trailing yield: 2.8%. Lower than top quartile of Swiss dividend payers (4.2%). In line with average of industry peers (2.6%).Buying Opportunity • Mar 01Now 20% undervaluedOver the last 90 days, the stock is up 7.8%. The fair value is estimated to be CHF95.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 3.9% per annum. Earnings is also forecast to grow by 8.8% per annum over the same time period.Buying Opportunity • Feb 10Now 19% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be CHF98.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.1% per annum. Earnings is also forecast to grow by 8.7% per annum over the same time period.Reported Earnings • Feb 10Full year 2022 earnings released: EPS: CHF3.09 (vs CHF3.45 in FY 2021)Full year 2022 results: EPS: CHF3.09 (down from CHF3.45 in FY 2021). Revenue: CHF11.4b (up 2.1% from FY 2021). Net income: CHF201.1m (down 10% from FY 2021). Profit margin: 1.8% (down from 2.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 10% per year.お知らせ • Dec 31Pascal Raffy agreed to acquire 25% stake in Bovet Fleurier S.A. from DKSH Holding AG (SWX:DKSH).Pascal Raffy agreed to acquire 25% stake in Bovet Fleurier S.A. from DKSH Holding AG (SWX:DKSH) on December 29, 2022. The transaction does not materially affect DKSH's profit and loss statement.お知らせ • Dec 16+ 1 more updateDKSH Holding AG to Report Fiscal Year 2022 Results on Feb 09, 2023DKSH Holding AG announced that they will report fiscal year 2022 results on Feb 09, 2023Buying Opportunity • Dec 07Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.3%. The fair value is estimated to be CHF87.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 7.3%. For the next 3 years, revenue is forecast to grow by 3.4% per annum. Earnings is also forecast to grow by 4.3% per annum over the same time period.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Chairman of the Board Marco Gadola was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Buying Opportunity • Nov 12Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 8.6%. The fair value is estimated to be CHF92.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 7.3%. Revenue is forecast to grow by 8.5% in 2 years. Earnings is forecast to grow by 2.7% in the next 2 years.お知らせ • Nov 08DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai.DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai on November 7, 2022.お知らせ • Nov 01DKSH Holding AG acquired 80% stake in Terra Firma.DKSH Holding AG agreed to acquire 80% stake in Terra Firma on September 22, 2022. The remainder stake will be held by Terra Firma's existing management team. Frank Gerhard, Jürg Frick and Eduard De Zordi of Homburger AG acted as legal advisor to DKSH Holding AG. BofA Securities acted as financial advisor to DKSH. DKSH Holding AG completed the acquisition of 80% stake in Terra Firma November 01, 2022.お知らせ • Sep 24DKSH Holding AG agreed to acquire Terra Firma.DKSH Holding AG agreed to acquire an 80% stake in Terra Firma on September 22, 2022. The remainder stake will be held by Terra Firma's existing management team. Frank Gerhard, Jürg Frick and Eduard De Zordi of Homburger AG acted as legal advisor to DKSH Holding AG.収支内訳DKSH Holding の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史SWX:DKSH 収益、費用、利益 ( )CHF Millions日付収益収益G+A経費研究開発費30 Jun 2611,04021211031 Mar 2611,06520811031 Dec 2511,09020311030 Sep 2511,14019912030 Jun 2511,19019512031 Mar 2511,14920512031 Dec 2411,10921512030 Sep 2411,00620214030 Jun 2410,90319015031 Mar 2410,99618615031 Dec 2311,08918215030 Sep 2311,22319216030 Jun 2311,35720217031 Mar 2311,34820117031 Dec 2211,33920117030 Sep 2211,29022217030 Jun 2211,24224416031 Mar 2211,18323416031 Dec 2111,12322416030 Sep 2111,01920315030 Jun 2110,91518314031 Mar 2110,83617014031 Dec 2010,75715714030 Sep 2011,02816016030 Jun 2011,29916318031 Mar 2011,43916818031 Dec 1911,57917318030 Sep 1911,43720062030 Jun 1911,294227106031 Mar 1911,329241106031 Dec 1811,363255106030 Sep 1811,386233104030 Jun 1811,408212102031 Mar 1811,214209102031 Dec 1711,019207102030 Sep 1710,869208102030 Jun 1710,719210101031 Mar 1710,612209101031 Dec 1610,505209101030 Sep 1610,336195101030 Jun 1610,166182102031 Mar 1610,108192102031 Dec 1510,051203102030 Sep 1510,110207950質の高い収益: DKSHは 高品質の収益 を持っています。利益率の向上: DKSHの現在の純利益率 (1.9%)は、昨年(1.7%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: DKSHの収益は過去 5 年間で年間1.1%減少しました。成長の加速: DKSHの過去 1 年間の収益成長率 ( 8.6% ) は、5 年間の平均 ( 年間-1.1%を上回っています。収益対業界: DKSHの過去 1 年間の収益成長率 ( 8.6% ) Trade Distributors業界9.2%を上回りませんでした。株主資本利益率高いROE: DKSHの 自己資本利益率 ( 12.4% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YCapital-goods 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/31 14:58終値2026/07/31 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DKSH Holding AG 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Anil ShenoyBarclaysChiara Di GiammariaBerenbergAndrew GroblerBNP Paribas13 その他のアナリストを表示
Reported Earnings • Jul 19First half 2026 earnings released: EPS: CHF1.67 (vs CHF1.41 in 1H 2025)First half 2026 results: EPS: CHF1.67 (up from CHF1.41 in 1H 2025). Revenue: CHF5.48b (flat on 1H 2025). Net income: CHF101.1m (up 10% from 1H 2025). Profit margin: 1.8% (in line with 1H 2025). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has fallen by 1% per year.
お知らせ • Jun 19+ 1 more updateDKSH Holding AG to Report First Half, 2027 Results on Jul 19, 2027DKSH Holding AG announced that they will report first half, 2027 results on Jul 19, 2027
Reported Earnings • Feb 19Full year 2025 earnings released: EPS: CHF3.12 (vs CHF3.31 in FY 2024)Full year 2025 results: EPS: CHF3.12 (down from CHF3.31 in FY 2024). Revenue: CHF11.1b (flat on FY 2024). Net income: CHF202.9m (down 5.5% from FY 2024). Profit margin: 1.8% (down from 1.9% in FY 2024). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 20First half 2025 earnings: EPS misses analyst expectationsFirst half 2025 results: EPS: CHF1.41 (down from CHF1.71 in 1H 2024). Revenue: CHF5.53b (up 1.5% from 1H 2024). Net income: CHF91.8m (down 17% from 1H 2024). Profit margin: 1.7% (down from 2.0% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 9% per year.
お知らせ • Jun 20+ 1 more updateDKSH Holding AG to Report Fiscal Year 2025 Results on Feb 17, 2026DKSH Holding AG announced that they will report fiscal year 2025 results on Feb 17, 2026
お知らせ • Mar 07DKSH Holding AG to Report First Half, 2025 Results on Jul 17, 2025DKSH Holding AG announced that they will report first half, 2025 results on Jul 17, 2025
分析記事 • Jul 22Analysts Are Updating Their DKSH Holding AG (VTX:DKSH) Estimates After Its Interim ResultsLast week, you might have seen that DKSH Holding AG ( VTX:DKSH ) released its half-yearly result to the market. The...
Reported Earnings • Jul 19First half 2026 earnings released: EPS: CHF1.67 (vs CHF1.41 in 1H 2025)First half 2026 results: EPS: CHF1.67 (up from CHF1.41 in 1H 2025). Revenue: CHF5.48b (flat on 1H 2025). Net income: CHF101.1m (up 10% from 1H 2025). Profit margin: 1.8% (in line with 1H 2025). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has fallen by 1% per year.
ナラティブ更新 • Jul 17DKSH: Expanded Asia Healthcare Partnerships Will Support Undervalued Distribution PlatformAnalysts have raised their price target on DKSH Holding to CHF 74.75 from CHF 72.57. They cite the company’s differentiated Asia exposure, as well as margin expansion and valuation re-rating potential highlighted in recent research.
ライブニュース • Jul 07DKSH Expands Lilly Partnership to Cover Hong Kong and Macau Healthcare MarketsDKSH Holding has entered a partnership with Eli Lilly Export S.A. to sell, promote and distribute Lilly’s pharmaceutical products in Hong Kong SAR and Macau SAR, extending an existing collaboration that already covers Singapore and Vietnam. The arrangement uses DKSH’s healthcare infrastructure and commercial platform in the region, while Lilly’s patient support programs in Hong Kong and Macau are expected to remain fully operational under the new setup. DKSH’s share price is at CHF64.20, with the stock up 9.6% year to date. By deepening its relationship with a global pharmaceutical group like Eli Lilly, DKSH is adding scale and relevance to its healthcare segment in two dense, higher-income markets, which concentrates execution risk around product availability, regulatory compliance and service quality in those territories.
お知らせ • Jun 19+ 1 more updateDKSH Holding AG to Report First Half, 2027 Results on Jul 19, 2027DKSH Holding AG announced that they will report first half, 2027 results on Jul 19, 2027
お知らせ • Mar 30+ 1 more updateDKSH Holding AG Approves Board ElectionsDKSH Holding AG announced at annual general meeting held on March 27, 2026, the shareholders elected Corine Tap, and Julie von Wedel-Keller as new members of the Board of Directors.
Upcoming Dividend • Mar 24Upcoming dividend of CHF2.50 per shareEligible shareholders must have bought the stock before 31 March 2026. Payment date: 02 April 2026. Payout ratio is on the higher end at 80%, however this is supported by cash flows. Trailing yield: 4.3%. Within top quartile of Swiss dividend payers (3.6%). Higher than average of industry peers (2.6%).
お知らせ • Mar 23DKSH Holding AG(SWX:DKSH) dropped from FTSE All-World Index (USD)DKSH Holding AG(SWX:DKSH) dropped from FTSE All-World Index (USD)
お知らせ • Mar 06DKSH Holding AG, Annual General Meeting, Mar 27, 2026DKSH Holding AG, Annual General Meeting, Mar 27, 2026, at 10:00 W. Europe Standard Time.
Reported Earnings • Feb 19Full year 2025 earnings released: EPS: CHF3.12 (vs CHF3.31 in FY 2024)Full year 2025 results: EPS: CHF3.12 (down from CHF3.31 in FY 2024). Revenue: CHF11.1b (flat on FY 2024). Net income: CHF202.9m (down 5.5% from FY 2024). Profit margin: 1.8% (down from 1.9% in FY 2024). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • Feb 18DKSH Holding AG announces Annual dividend, payable on April 02, 2026DKSH Holding AG announced Annual dividend of CHF 2.5000 per share payable on April 02, 2026, ex-date on March 31, 2026 and record date on April 01, 2026.
ナラティブ更新 • Feb 11DKSH: Potential Swixx Acquisition Will Support Undervalued Healthcare Distribution PlatformAnalysts have maintained their price target for DKSH Holding at around CHF 72.57. This suggests only very small adjustments in assumptions for the discount rate, long-term revenue growth, profit margin and future P/E to reflect updated risk and earnings expectations.
ナラティブ更新 • Jan 27DKSH: Future Healthcare And Consumer Distribution Deals Will Support Undervalued SharesAnalysts have nudged their price target for DKSH Holding slightly higher, with fair value rising from CHF 72.17 to about CHF 72.57. This reflects small adjustments to assumptions around the discount rate, modestly stronger revenue growth, a marginally softer profit margin and a slightly higher future P/E multiple.
お知らせ • Jan 16DKSH Management AG Announces Retirement of Thomas Sul from the Role as Co-Head and Member of the Executive CommitteeDKSH Management AG announced that Thomas Sul, Co-Head of the Business Unit Performance Materials and Member of the Executive Committee, has decided to gradually scale down his activities as he eases into retirement and has stepped down from his role as Co-Head and Member of the Executive Committee. Natale Capri, who has served as Co-Head for over ten years, assumes full responsibility as Head of the Business Unit Performance Materials and will remain a Member of the Executive Committee. After nearly 30 years at DKSH, Thomas Sul leaves behind a remarkable legacy. Under his co-leadership, Performance Materials has achieved significant milestones, including driving globalization, strengthening business development, realizing multiple acquisitions, and doubling operating profit. Thomas will continue to contribute his expertise in a strategic capacity after scaling down his activities in the first quarter of 2026.
ナラティブ更新 • Jan 12DKSH: Future Asia Distribution Deals Will Support Undervalued Share PriceAnalysts have trimmed their price target on DKSH Holding to about CHF 72, down from roughly CHF 74, citing updated assumptions for fair value, discount rate, revenue growth, profit margins and a slightly higher future P/E multiple. What's in the News DKSH is reported to be among potential bidders for Swiss pharmaceutical distributor Swixx Biopharma, with the target company said to be valued in a range of €1.5b to €2b.
お知らせ • Dec 19DKSH Holding AG (SWX:DKSH) agreed to acquire Biomedic Science Material Joint Stock Company.DKSH Holding AG (SWX:DKSH) agreed to acquire Biomedic Science Material Joint Stock Company on December 17, 2025. For the period ending December 31, 2024, Biomedic Science Material Joint Stock Company reported total revenue of CHF 12 million. The expected completion of the transaction is January 1, 2026 to March 31, 2026.
分析記事 • Dec 15DKSH Holding (VTX:DKSH) Has More To Do To Multiply In Value Going ForwardIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
お知らせ • Nov 22DKSH Management Ltd. Announces Executive ChangesDKSH Management Ltd. announced the appointment of Patrik Grande as new Head Business Unit Healthcare as of January 2026. Currently Vice President, Commercial Outsourcing & Cluster Head APAC, he will be a member of DKSH's Executive Committee, report to CEO Stefan P. Butz, and will relocate from Bangkok to Singapore within the next year. Patrik Grande follows Bijay Singh who will begin his retirement on March 31, 2026, after eleven years at DKSH. Patrik Grande is a well-seasoned and accomplished leader with more than 20 years of experience in the global pharmaceutical industry. He joined DKSH in 2022 as Vice President, Business Unit Healthcare Thailand, following a successful two-decade career at Novartis. During his time at Novartis, he held increasingly senior leadership roles across multiple markets, including South Korea, Malaysia, the United Kingdom, Switzerland, Russia, and Spain. Since joining DKSH, Patrik has revitalized the Healthcare business in Thailand and delivered growth. In his role as Vice President, Commercial Outsourcing & Cluster Head APAC, he strengthened the strategic commercial outsourcing pillar, expanded the robust regional capabilities, delivering growth and driving strategic progress across the region. A Spanish citizen, Patrik holds a Master's degree in Business Administration from IESE Business School. Bijay Singh leaves behind an outstanding legacy after eleven years at DKSH, including nearly nine years as Head Business Unit Healthcare and Member of the Executive Committee. Bijay Singh joined DKSH as Vice President, Global Business Development for Business Unit Healthcare in 2015. His tenure was marked by significant achievements such as building robust commercial outsourcing capabilities, driving strategic M&As, expanding the Healthcare business into new markets such as Australia, the Philippines, and South Korea, and fostering a strong talent pipeline.
お知らせ • Nov 18DKSH Reportedly to Weigh Bid for Pharma Distributor Swixx BiopharmaDKSH Holding AG (SWX:DKSH) is among the companies exploring a potential acquisition of Swiss pharmaceutical distributor Swixx Biopharma (Swixx Biopharma SA), Bloomberg News reported on November 16, 2025, citing people familiar with the matter. Private-equity firms SK Capital Partners (SK Capital Partners, LP) and Lone Star (Lone Star Americas Acquisitions, Inc.) are also said to be evaluating bids. The sources indicated that Swixx could fetch EUR 1.5 billion to EUR 2 billion ($1.7 billion to $2.2 billion), though talks are ongoing and may not lead to a deal. Additional bidders could still join the process. Swixx, jointly owned by HBM Healthcare Investments and members of its management team, specializes in helping drugmakers navigate distribution in smaller and more regulated markets. The company operates in 44 countries and recorded EUR 900 million in 2023 revenue, according to its website. Zurich-based DKSH, valued at roughly CHF 3.5 billion, runs a similar distribution and marketing platform spanning healthcare, consumer goods, technology and industrial materials. Representatives for DKSH, Lone Star and HBM declined to comment to Bloomberg News. SK Capital did not respond to a request for comment, and Swixx could not be reached.
分析記事 • Nov 16The Price Is Right For DKSH Holding AG (VTX:DKSH)With a median price-to-earnings (or "P/E") ratio of close to 20x in Switzerland, you could be forgiven for feeling...
ナラティブ更新 • Sep 06Asia Pacific Expansion And Digitalization Will Fuel Sustainable SuccessThe consensus analyst price target for DKSH Holding has been revised downward, reflecting modest declines in both revenue growth forecasts and the future P/E ratio, resulting in a new fair value of CHF74.00. What's in the News DKSH Consumer Goods has partnered with Nextfood Global to launch premium breakfast cereals and freeze-dried fruit snacks in Singapore, targeting health-conscious, urban consumers.
分析記事 • Aug 26DKSH Holding (VTX:DKSH) Hasn't Managed To Accelerate Its ReturnsDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...
分析記事 • Aug 08DKSH Holding (VTX:DKSH) Seems To Use Debt Quite SensiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Jul 20First half 2025 earnings: EPS misses analyst expectationsFirst half 2025 results: EPS: CHF1.41 (down from CHF1.71 in 1H 2024). Revenue: CHF5.53b (up 1.5% from 1H 2024). Net income: CHF91.8m (down 17% from 1H 2024). Profit margin: 1.7% (down from 2.0% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 9% per year.
お知らせ • Jun 20+ 1 more updateDKSH Holding AG to Report Fiscal Year 2025 Results on Feb 17, 2026DKSH Holding AG announced that they will report fiscal year 2025 results on Feb 17, 2026
お知らせ • May 21DKSH Holding AG (SWX:DKSH) signed an agreement to acquire A.P.N Plastics Pty Ltd.DKSH Holding AG (SWX:DKSH) signed an agreement to acquire A.P.N Plastics Pty Ltd on May 20, 2025. DKSH will acquire the entire business and fully integrate the company into its existing operations. APN Plastics generates annual net sales of more than CHF 25 million. The transaction is subject to customary closing conditions. The closing of the transaction is expected during the second quarter of 2025.
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CHF58.70, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 15x in the Trade Distributors industry in Europe. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CHF94.58 per share.
お知らせ • Mar 29DKSH Holding AG Announces Board ChangesDKSH Holding AG at its Annual General Meeting held on 27 March 2025, announced Dr. Hans Christoph Tanner did not stand for reelection. Suwannee Ratthayabandith was elected as a new member of the Board of Directors.
Upcoming Dividend • Mar 24Upcoming dividend of CHF2.35 per shareEligible shareholders must have bought the stock before 31 March 2025. Payment date: 02 April 2025. Payout ratio is a comfortable 71% and this is well supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of Swiss dividend payers (4.0%). Higher than average of industry peers (2.4%).
お知らせ • Mar 07DKSH Holding AG to Report First Half, 2025 Results on Jul 17, 2025DKSH Holding AG announced that they will report first half, 2025 results on Jul 17, 2025
お知らせ • Feb 28DKSH Holding AG, Annual General Meeting, Mar 27, 2025DKSH Holding AG, Annual General Meeting, Mar 27, 2025, at 10:00 W. Europe Standard Time.
新しいナラティブ • Feb 23New Partnerships With Alcon And Ichitan Will Expand Market Presence And Efficiency Strategic priorities and M&A partnerships are set to enhance market position and drive significant revenue and earnings growth.
Reported Earnings • Feb 13Full year 2024 earnings released: EPS: CHF3.31 (vs CHF2.80 in FY 2023)Full year 2024 results: EPS: CHF3.31 (up from CHF2.80 in FY 2023). Revenue: CHF11.1b (flat on FY 2023). Net income: CHF214.8m (up 18% from FY 2023). Profit margin: 1.9% (up from 1.6% in FY 2023). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 1% per year.
お知らせ • Jan 07DKSH Holding AG (SWX:DKSH) acquired Clmo Technology Sdn. Bhd.DKSH Holding AG (SWX:DKSH) acquired Clmo Technology Sdn. Bhd. on January 7, 2025. Clmo Technology Sdn. Bhd.'s management team will join DKSH Holding AG’s business unit technology. DKSH Holding AG (SWX:DKSH) completed the acquisition of Clmo Technology Sdn. Bhd. on January 7, 2025.
お知らせ • Dec 06DKSH Holding AG to Report Fiscal Year 2024 Results on Feb 12, 2025DKSH Holding AG announced that they will report fiscal year 2024 results on Feb 12, 2025
お知らせ • Nov 13DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare DistributionDKSH Healthcare Business Unit, in partnership with Euris, is introducing ConnectPlus, a data-driven Customer Relationship Management (CRM) and Multi-Channel Engagement (MCE) platform aimed at transforming healthcare distribution across the Asia Pacific region. Designed to enhance productivity and operational efficiency, this platform provides a 360° view of healthcare professionals, streamlines MCE, and strengthens DKSH Healthcare's ability to tailor interactions and marketing strategies. The roll-out will start in Thailand in January 2025. With this new platform DKSH Healthcare reinforces its dedication to commercial excellence by enlarging possibilities and improving interactions with clients, customers, and patients. The introduction of ConnectPlus underscores DKSH Healthcare's commitment to harnessing digital solutions that orchestrate and maximize impact of both client and patient interactions, while upholding a high standard of operational excellence. ConnectPlus empowers DKSH to tap into the vast potential provided by the global healthcare big data market by delivering precise, targeted engagement strategies that cater to the unique needs of healthcare professionals, clients, and patients across the region. Furthermore, ConnectPlus is strategically designed to leverage the existing preference of face-to-face sales visits, by orchestrating personalized digital touchpoints, based on data driven insights, to prepare and enhance in-person interactions. The platform's ability to blend in-person and digital strategies is essential for maximizing outreach and driving meaningful engagement. By integrating advanced AI and analytics, ConnectPlus not only streamlines communication and marketing efforts but also personalizes interactions based on real-time data, ensuring relevance and impact. This marks a crucial milestone in DKSH Healthcare's journey towards fully integrating digital innovation into its operations, reinforcing its leadership in driving agility and efficiency within the rapidly evolving healthcare landscape.
Reported Earnings • Jul 18First half 2024 earnings released: EPS: CHF1.71 (vs CHF1.59 in 1H 2023)First half 2024 results: EPS: CHF1.71 (up from CHF1.59 in 1H 2023). Revenue: CHF5.45b (down 3.3% from 1H 2023). Net income: CHF111.2m (up 7.5% from 1H 2023). Profit margin: 2.0% (up from 1.8% in 1H 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 4% per year.
Upcoming Dividend • Mar 21Upcoming dividend of CHF2.25 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 03 April 2024. Payout ratio is on the higher end at 80%, however this is supported by cash flows. Trailing yield: 3.6%. Lower than top quartile of Swiss dividend payers (4.1%). Higher than average of industry peers (2.2%).
Declared Dividend • Feb 29Dividend increased to CHF2.25Dividend of CHF2.25 is 4.7% higher than last year. Ex-date: 28th March 2024 Payment date: 3rd April 2024 Dividend yield will be 3.5%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is covered by both earnings (80% earnings payout ratio) and cash flows (43% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 30% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Feb 18Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: EPS: CHF2.80 (down from CHF3.10 in FY 2022). Revenue: CHF11.1b (down 2.2% from FY 2022). Net income: CHF182.0m (down 9.5% from FY 2022). Profit margin: 1.6% (down from 1.8% in FY 2022). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.3%. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 2% per year.
お知らせ • Dec 23+ 2 more updatesDKSH Holding AG to Report First Half, 2024 Results on Jul 16, 2024DKSH Holding AG announced that they will report first half, 2024 results on Jul 16, 2024
Price Target Changed • Nov 21Price target decreased by 7.4% to CHF73.90Down from CHF79.80, the current price target is an average from 6 analysts. New target price is 31% above last closing price of CHF56.50. Stock is down 22% over the past year. The company is forecast to post earnings per share of CHF3.16 for next year compared to CHF3.09 last year.
お知らせ • Sep 19DKSH Holding AG (SWX:DKSH) agreed to acquire CS Company Ltd.DKSH Holding AG (SWX:DKSH) agreed to acquire CS Company Ltd on September 18, 2023. CS Company generates net sales of over CHF 35 million. The deal is expected to close in the fourth quarter, subject to certain conditions.
Reported Earnings • Jul 20First half 2023 earnings released: EPS: CHF1.59 (vs CHF1.58 in 1H 2022)First half 2023 results: EPS: CHF1.59 (up from CHF1.58 in 1H 2022). Revenue: CHF5.63b (flat on 1H 2022). Net income: CHF103.4m (flat on 1H 2022). Profit margin: 1.8% (in line with 1H 2022). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Buying Opportunity • Jun 22Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 8.1%. The fair value is estimated to be CHF83.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 3.6% per annum. Earnings is also forecast to grow by 8.7% per annum over the same time period.
お知らせ • May 31DKSH Holding AG to Report First Half, 2023 Results on Jul 18, 2023DKSH Holding AG announced that they will report first half, 2023 results on Jul 18, 2023
Buying Opportunity • May 17Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 15%. The fair value is estimated to be CHF84.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 3.6% per annum. Earnings is also forecast to grow by 8.7% per annum over the same time period.
Price Target Changed • May 12Price target decreased by 12% to CHF70.83Down from CHF80.83, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of CHF69.85. Stock is down 14% over the past year. The company is forecast to post earnings per share of CHF3.34 for next year compared to CHF3.09 last year.
お知らせ • May 11DKSH Appoints Chris Ritchie as New Head Business Unit Consumer GoodsDKSH announced the appointment of Chris Ritchie as new Head Business Unit Consumer Goods as of mid-August 2023. Based in Singapore, he will be a member of DKSH's Executive Committee and report to CEO Stefan P. Butz. Chris Ritchie follows Terry Seremetis, who, after four years, decided to pursue his career opportunities outside of DKSH as announced on January 3, 2023. Chris Ritchie has 28 years of experience in the consumer goods industry. For the last four years, he was Chief Global Business Officer of Sazerac, a leading privately held American spirit company, where he oversaw operations in Asia Pacific and Europe. From 2016 to 2019, he was General Manager at Reckitt Benckiser, responsible for the growth market Philippines. Prior to that, from 2007 to 2016, he held various General Manager and Director positions at SABMiller in Asia, Europe, and Americas, including Managing Director of SABMiller Vietnam. From 1995 to 2006, he held regional and global marketing roles at P&G. Throughout his career, Chris has driven growth, route-to-market, and built strong teams, especially in developing markets. A Canadian citizen,Chris (50 years) holds a Bachelor's degree in Economics from Queen's University in Kingston, Canada.
Buying Opportunity • Mar 18Now 21% undervaluedOver the last 90 days, the stock is up 3.3%. The fair value is estimated to be CHF92.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 3.9% per annum. Earnings is also forecast to grow by 8.9% per annum over the same time period.
Upcoming Dividend • Mar 13Upcoming dividend of CHF2.15 per share at 2.8% yieldEligible shareholders must have bought the stock before 20 March 2023. Payment date: 22 March 2023. Payout ratio is a comfortable 69% and this is well supported by cash flows. Trailing yield: 2.8%. Lower than top quartile of Swiss dividend payers (4.2%). In line with average of industry peers (2.6%).
Buying Opportunity • Mar 01Now 20% undervaluedOver the last 90 days, the stock is up 7.8%. The fair value is estimated to be CHF95.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 3.9% per annum. Earnings is also forecast to grow by 8.8% per annum over the same time period.
Buying Opportunity • Feb 10Now 19% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be CHF98.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.1% per annum. Earnings is also forecast to grow by 8.7% per annum over the same time period.
Reported Earnings • Feb 10Full year 2022 earnings released: EPS: CHF3.09 (vs CHF3.45 in FY 2021)Full year 2022 results: EPS: CHF3.09 (down from CHF3.45 in FY 2021). Revenue: CHF11.4b (up 2.1% from FY 2021). Net income: CHF201.1m (down 10% from FY 2021). Profit margin: 1.8% (down from 2.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 10% per year.
お知らせ • Dec 31Pascal Raffy agreed to acquire 25% stake in Bovet Fleurier S.A. from DKSH Holding AG (SWX:DKSH).Pascal Raffy agreed to acquire 25% stake in Bovet Fleurier S.A. from DKSH Holding AG (SWX:DKSH) on December 29, 2022. The transaction does not materially affect DKSH's profit and loss statement.
お知らせ • Dec 16+ 1 more updateDKSH Holding AG to Report Fiscal Year 2022 Results on Feb 09, 2023DKSH Holding AG announced that they will report fiscal year 2022 results on Feb 09, 2023
Buying Opportunity • Dec 07Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.3%. The fair value is estimated to be CHF87.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 7.3%. For the next 3 years, revenue is forecast to grow by 3.4% per annum. Earnings is also forecast to grow by 4.3% per annum over the same time period.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Chairman of the Board Marco Gadola was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Buying Opportunity • Nov 12Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 8.6%. The fair value is estimated to be CHF92.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 7.3%. Revenue is forecast to grow by 8.5% in 2 years. Earnings is forecast to grow by 2.7% in the next 2 years.
お知らせ • Nov 08DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai.DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai on November 7, 2022.
お知らせ • Nov 01DKSH Holding AG acquired 80% stake in Terra Firma.DKSH Holding AG agreed to acquire 80% stake in Terra Firma on September 22, 2022. The remainder stake will be held by Terra Firma's existing management team. Frank Gerhard, Jürg Frick and Eduard De Zordi of Homburger AG acted as legal advisor to DKSH Holding AG. BofA Securities acted as financial advisor to DKSH. DKSH Holding AG completed the acquisition of 80% stake in Terra Firma November 01, 2022.
お知らせ • Sep 24DKSH Holding AG agreed to acquire Terra Firma.DKSH Holding AG agreed to acquire an 80% stake in Terra Firma on September 22, 2022. The remainder stake will be held by Terra Firma's existing management team. Frank Gerhard, Jürg Frick and Eduard De Zordi of Homburger AG acted as legal advisor to DKSH Holding AG.
